Regeneron Pharmaceuticals reported strong second-quarter financials but encountered regulatory setbacks. The FDA delayed approvals for three high-dose Eylea applications due to manufacturing issues at a Catalent facility now owned by Novo Nordisk. Additionally, the agency issued a complete response letter for odronextamab, a bispecific antibody for relapsed follicular lymphoma, citing impacts from the same manufacturing challenges. Despite these hurdles, Regeneron's revenues rose 4% year-over-year and surpassed analyst expectations, with earnings per share significantly ahead of forecasts.